While proof-of-concept studies have supported beneficial effects of exenatide [14–17] in patients with Parkinson’s disease, data with GLP-1-RA in AD/MCI are scant and not conclusive [18–20] and mainly limited to a few pilot studies in the overt clinical and irreversible AD phase. The gene discussed is GLP1R; the disease is Alzheimer disease.